• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·China·Healthcare·000908.SZ
Share

CSPC Hunan Jingfeng Pharmaceutical Co., Ltd. Stocks

CN¥ 6.85Last Updated 13.07.2026

Issuer Rating

2/7
Performance

Poor

Risk

Considerable

Recommendation

Sell

Market Cap

CN¥ 870.90M

CN¥ 6.85
Key Takeaways

Risk factor

Weak & very vulnerable to price shocks

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly overvalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Hunan Jingfeng Pharmaceutical Co.,Ltd., established in 2003 and headquartered in Shanghai, China, operates as a manufacturer and supplier of various pharmaceutical products, including chemical compounds and biological agents, within the Chinese market. A prominent offering from the company is its sodium hyaluronate injection, which finds extensive application in both orthopedic and surgical fields. Beyond this, their product range encompasses ophthalmology solutions and Active Pharmaceutical Ingredients (APIs). The firm also dedicates resources to the research and development of medications for anti-tumor, cancer, and cardiovascular conditions, alongside providing a selection of skincare products.

Company Valuation

Greatly overvalued
1/7

Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers. Specifically, the stock is overpriced on P/FCF.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

13.07.2026 20:30

Shares of a small software developer soared following news of its possible sale

13.07.2026 19:53

Trump announced the resumption of the blockade of the Strait of Hormuz against Iranian vessels

13.07.2026 19:20

Volkswagen has announced plans to lay off another 50,000 employees to cut costs

13.07.2026 18:52

Kazakhstani banks topped The Banker's rankings for profitability and capital growth in Asia

13.07.2026 18:41

Chipmakers' sell-off and a new escalation in Iran: How the market opened

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026